Business
Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
Enrollment Completed in C-BEYOND Phase 3 Trial with More Than 880 HCV Treatment-Naïve Patients in US and Canada C-BEYOND Topline Results Expected Mid-2026 C-FORWARD Phase 3 Trial, Conducted Outside North America, Enrollment Completion Expected Mid-2026 with Topline Results Anticipated Year-End 2026 C-BEYOND AND C-FORWARD are the First Global Phase 3 Head-to-Head Trials of Direct-Acting Antivirals for Treatment of HCV BOSTON, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: A
About this update from Atea Pharmaceuticals, Inc.
[{"type":"image","alt":"Atea Pharmaceuticals, Inc.","displaySize":"","headline":null,"caption":"Atea Pharmaceuticals, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":170,"url":"https://media.zenfs.com/en/globenewswire.com/ef3965acbb5b5bff1eabb7e1952ded30"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/KXeoz412fc_7VPFgx2isiw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIzODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/ef3965acbb5b5bff1eabb7e1952ded30","width":300,"height":170}},"lazy":false},{"type":"text","content":"Enrollment Completed in C-BEYOND Phase 3 Trial with More Than 880 HCV Treatment-Naïve Patients in US and Canada","length":111,"tagName":"p"},{"type":"text","content":"C-BEYOND Topline Results Expected Mid-2026","length":42,"tagName":"p"},{"type":"text","content":"C-FORWARD Phase 3 Trial, Conducted Outside North America, Enrollment Completion Expected Mid-2026 with Topline Results Anticipated Year-End 2026","length":144,"tagName":"p"},{"type":"text","content":"C-BEYOND AND C-FORWARD are the First Global Phase 3 Head-to-Head Trials of Direct-Acting Antivirals for Treatment of HCV","length":120,"tagName":"p"},{"type":"text","content":"BOSTON, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced completion of enrollment of more than 880 treatment-naïve patients in the C-BEYOND Phase 3 trial evaluating the fixed-dose combination (FDC) regimen of bemnifosbuvir and ruzasvir compared to the FDC regimen of sofosbuvir and velpatasvir for the treatment of hepatitis C virus (HCV). C-BEYOND is being conducted at approximately 120 clinical trial sites in the US and Canada. Phase 3 topline results are expected mid-year 2026.","length":688,"tagName":"p"},{"type":"text","content":"In addition to C-BEYOND, Atea continues to advance enrollment of treatment-naïve patients in C-FORWARD, a Phase 3 trial evaluating this same FDC regimen in 880 patients at approximately 120 clinical trial sites in up to 17 countries outside of North America. Completion of enrollment in C-FORWARD is expected mid-year 2026, with Phase 3 topline results anticipated year-end 2026. In both studies, the FDC regimen of bemnifosbuvir and ruzasvir...